Lipogems Announces Last Patient Enrolled in the U.S. FDA IDE ARISE Study for the Treatment of Knee Osteoarthritis
LipogemsLipogems, a clinical stage- global medical technology company, announces it has completed enrollment in the ARISE I U.S. FDA IDE study, which aims to examine MicroFat versus corticosteriod injection for the treatment of Knee Osteoarthritis (OA). Efficacy and safety results from ARISE 1 are expected to be announced in 2025.